BrightSpring Earnings Call Highlights Growth Amid Headwinds

BrightSpring Health Services, Inc. ((BTSG)) has held its Q1 earnings call. Read on for the main highlights of the call.

BrightSpring Health Services used its latest earnings call to showcase strong momentum but a mixed backdrop. Management highlighted double-digit revenue growth, a 45% jump in adjusted EBITDA and expanding margins, underscoring healthy execution in core pharmacy and provider segments. At the same time, they were candid about sizable but well-telegraphed headwinds from drug pricing reforms and brand-to-generic shifts, stressing that these pressures are manageable and already embedded in guidance.

Strong Top-Line Growth Across Core Segments

BrightSpring reported Q1 2026 revenue of $3.6 billion, up 26% year over year and above many peers in the healthcare services space. Pharmacy Solutions drove most of the expansion with $3.2 billion in sales, up 25%, while Provider Services added $442 million and grew even faster at 28%, highlighting balanced growth across the portfolio.

Profitability Surges with Margin Expansion

Profitability kept pace with revenue as adjusted EBITDA rose 45% to $190 million, lifting the adjusted EBITDA margin to 5.3%, about 70 basis points higher than a year ago. Adjusted EPS landed at $0.39, signaling that the company is converting growth into earnings despite incremental corporate investment and regulatory headwinds.

Specialty and Infusion Pharmacy Power the Engine

Specialty and infusion operations remained the core growth engine, with revenue reaching $2.6 billion, a robust 36% increase year over year. Scripts grew about 30% as specialty volumes outpaced infusion, and Pharmacy Solutions gross profit climbed 48% to $301 million while adjusted EBITDA rose 46% to $169 million, supported by a 92.1% medication possession ratio and a 4.6‑day time-to-first-fill.

Provider Services Gain from Home Health Integrations

Provider Services posted gross profit of $181 million, up 35%, and adjusted EBITDA of $66 million with margins near 15%, modestly higher than last year. Home Health revenue surged 49% to $266 million, aided by contributions from newly acquired Amedisys and LHC branches, which added about $79 million of revenue and roughly $9 million of adjusted EBITDA in Q1 as management targets about $30 million in first-year integration benefits.

Operational and Quality Metrics Underpin Growth

Management emphasized quality as a competitive differentiator, noting that over 91% of Home Health branches carry ratings of at least four stars and that more than 99% of patients receive timely initiation of care. Patient satisfaction and reliability metrics are similarly strong, with 94% satisfaction in infusion, 97% of discharges tied to therapy completion, and near-perfect accuracy and on-time delivery in Home and Community dispensing.

Cash Generation and Deleveraging Strengthen the Balance Sheet

BrightSpring generated $123 million of operating cash flow in Q1 excluding Community Living fees, demonstrating solid cash conversion. The company also closed the sale of its Community Living business for roughly $835 million gross, using the $811 million in net proceeds to reduce net debt to about $1.7 billion and improve leverage to 2.27 times, positioning the balance sheet for continued investment.

Home and Community Pharmacy Hit by IRA and Customer Exits

The Home and Community Pharmacy line remained a weak spot, with revenue falling 9% year over year to $527 million. Management pointed to about a $50 million impact in Q1 from the Inflation Reduction Act and from the deliberate exit of unprofitable customers, and they expect roughly a $45 million revenue drag per remaining quarter, totaling around $175 million of IRA-related pressure in 2026.

Managing Material Industry Headwinds

Beyond Home and Community, leadership reiterated a significant slate of headwinds, including about $181 million of specialty and infusion IRA effects and roughly $250 million tied to brand-to-generic transitions. These factors collectively align with the previously telegraphed $600 million revenue headwind, but the company believes it can offset around $15 million of associated EBITDA pressure through mix, efficiency and growth initiatives.

Increased Corporate and SG&A Investments

Corporate and SG&A expenses moved higher in the quarter as BrightSpring stepped up investments in information technology, salesforce expansion and commission structures. Management signaled that corporate costs may edge up further over the rest of the year as the company continues to fund growth platforms designed to support scale and mitigate long-term industry risks.

Tax and Financing Considerations in the Near Term

The Community Living divestiture comes with an estimated $100 million tax bill expected in the second quarter, a timing factor that will temporarily affect pro forma leverage metrics. Quarterly interest expense is anticipated at roughly $35 million, a level that investors will watch closely given the company’s deleveraging plans and continued appetite for selective strategic investments.

Competitive and PBM Dynamics Remain a Watch Point

Management flagged ongoing strategic moves by pharmacy benefit managers, including private-label and biosimilar strategies and efforts to direct volume toward their own pharmacies. While BrightSpring currently sees only limited direct exposure to these trends, the company acknowledged that PBM and payer behavior remains a key external risk factor that could influence volumes and economics over time.

Guidance and Forward Outlook

BrightSpring reaffirmed its 2026 outlook, calling for revenue between $14.725 billion and $15.225 billion, representing mid-teens growth ex-Community Living and led by $12.85 billion to $13.30 billion from Pharmacy Solutions. The company expects adjusted EBITDA of $795 million to $825 million, about $500 million in annual operating cash flow, leverage around 2.27 times before taxes on sale proceeds and continued IRA-related headwinds, but sees ample runway to grow earnings despite these pressures.

BrightSpring’s latest earnings call paints a picture of a company leaning into growth while navigating a more challenging regulatory and competitive environment. Strong momentum in specialty, infusion and home health, combined with disciplined cash generation and leverage reduction, provides a solid base, but investors will be watching how effectively management offsets IRA and PBM-related headwinds as the year progresses.